Evidence map›Paper›PMID 31758019›Full record

ArticleScientific reports2019

Engineering dual-glycan responsive expression systems for tunable production of heterologous proteins in Bacteroides thetaiotaomicron.

Darryl R Jones, Marshall B Smith, Richard McLean, Julie M Grondin, Carolyn R Amundsen, G Douglas Inglis, Brent Selinger, D Wade Abbott

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Complete genome sequence ofMicrobiology resource announcements · 2025
    Article
  3. Article
  4. A molecular toolkit for heterologous protein secretion acrossbioRxiv : the preprint server for biology · 2023
    Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Darryl R JonesLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada.
Marshall B SmithLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada.
Richard McLeanLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada.
Julie M GrondinLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada.ORCID http://orcid.org/0000-0002-3004-5715
Carolyn R AmundsenLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada.
G Douglas InglisLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada.ORCID http://orcid.org/0000-0003-1769-7863
Brent SelingerDepartment of Biological Sciences, University of Lethbridge, Lethbridge, Alberta, T1K 3M4, Canada.
D Wade AbbottLethbridge Research and Development Centre, Agriculture and Agri-Food Canada, Lethbridge, Alberta, T1J 4B1, Canada. wade.abbott@canada.ca.ORCID http://orcid.org/0000-0003-4893-5799
Agriculture and Agri-Food Canada · CAUniversity of Lethbridge · CA

Funding

Alberta Innovates BIOFS-12-026
6 · The paper itself

Abstract

Genetically engineering intestinal bacteria, such as Bacteroides thetaiotaomicron (B. theta), holds potential for creating new classes of biological devices, such as diagnostics or therapeutic delivery systems. Here, we have developed a series of B. theta strains that produce functional transgenic enzymes in response to dextran and arabinogalactan, two chemically distinct glycans. Expression systems for single glycan induction, and a novel "dual-glycan" expression system, requiring the presence of both dextran and arabinogalactan, have been developed. In addition, we have created two different chromosomal integration systems and one episomal vector system, compatible with engineered recipient strains, to improve the throughput and flexibility of gene cloning, integration, and expression in B. theta. To monitor activity, we have demonstrated the functionality of two different transgenic enzymes: NanoLuc, a luciferase, and BuGH16C, an agarase from the human intestinal bacterium, Bacteroides uniforms NP1. Together this expression platform provides a new collection of glycan-responsive tools to improve the strength and fidelity of transgene expression in B. theta and provides proof-of-concept for engineering more complex multi-glycan expression systems.

Indexed as

Genetic EngineeringBacteroides thetaiotaomicronChromosomes, BacterialGene Expression Regulation, BacterialGene OrderGene TargetingGenetic VectorsGlycoside HydrolasesHumansPlasmidsPolysaccharidesPromoter Regions, GeneticRecombinant ProteinsTransgenesagaraseGlycoside HydrolasesPolysaccharidesRecombinant Proteins

Identifiers

PMID31758019
PMCPMC6874557
OpenAlexW2967768859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.